Isovorin (Levoleucovorin)

Levoleucovorin is a reduced folic‑acid derivative that stabilises the binding of 5‑fluorouracil to thymidylate synthase, intensifying DNA synthesis inhibition in cancer cells, while also supplying reduced folates to normal tissues after methotrexate exposure.

The dose of Isovorin is determined by the prescribing clinician based on the specific chemotherapy protocol, patient weight, renal function and the timing relative to 5‑fluorouracil or methotrexate administration.

Safety data for levoleucovorin in pregnancy and lactation are limited. It should only be used when the potential benefit to the mother outweighs any possible risk to the fetus or infant, and under close medical supervision.

To order Isovorin, submit an enquiry on the product page at gnhindia.com with the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain if needed) and import documentation.

Isovorin contains levoleucovorin, the active stereoisomer of folinic acid, offering a more potent rescue effect at lower concentrations compared with racemic calcium folinate formulations. Clinical choice often depends on local guidelines, availability and specific chemotherapy regimens.

Isovorin should be stored at controlled room temperature, typically below 25 °C, in its original packaging. Protect the product from light, moisture and extreme temperature fluctuations to maintain stability.

Isovorin is supplied as a sterile injectable solution and is administered by intravenous or intramuscular injection, usually shortly after 5‑fluorouracil infusion or as a timed rescue following high‑dose methotrexate, according to the prescribing oncologist’s protocol.

Serious risks include anaphylactic or severe hypersensitivity reactions, renal impairment, cardiac arrhythmias, and significant reductions in blood cell counts such as neutropenia or thrombocytopenia, which require immediate medical attention.

Isovorin is contraindicated in patients with known hypersensitivity to levoleucovorin or any component of the formulation. Caution is also advised for individuals with severe renal dysfunction or those receiving incompatible antifolate agents.